Kratom is most often compared to opioids like morphine and oxycodone because its active compounds bind to the same receptors in the brain. But kratom is not a traditional opioid. It’s a tropical tree in the same plant family as coffee, and its effects fall somewhere between a mild stimulant at low doses and an opioid-like painkiller at higher doses. Understanding where kratom overlaps with and diverges from these better-known substances is key to understanding why it generates so much debate.
Kratom and Coffee Share a Family Tree
Kratom (Mitragyna speciosa) belongs to the Rubiaceae family, the same botanical group as the coffee plant. Both species produce leaves rich in bioactive compounds. Coffee produces caffeine, a central nervous system stimulant. Kratom produces a different set of alkaloids, primarily mitragynine and a smaller amount of 7-hydroxymitragynine, which interact with the brain’s opioid receptors rather than its adenosine system.
At low doses, some users describe kratom’s effects as coffee-like: increased energy, alertness, and mild mood elevation. This stimulant quality is one reason the comparison to coffee persists in popular discussion. But the resemblance ends quickly as the dose increases. Higher amounts of kratom produce sedation and pain relief that coffee never does, because the underlying chemistry is fundamentally different.
How Kratom Acts on Opioid Receptors
The closest pharmacological comparison for kratom is to opioid painkillers. Mitragynine, the most abundant alkaloid in kratom leaves, activates the mu-opioid receptor, the same receptor targeted by morphine, oxycodone, and heroin. However, mitragynine is a partial agonist, meaning it only partially activates that receptor rather than fully switching it on the way traditional opioids do. Its maximum activation of the human mu-opioid receptor reaches roughly 34% of the receptor’s full capacity.
Your liver converts some of the mitragynine you consume into a more potent compound called 7-hydroxymitragynine. This metabolite binds to the mu-opioid receptor with 5 to 23 times greater affinity than mitragynine itself, and it activates the receptor more strongly (about 47% of full capacity). In animal studies, 7-hydroxymitragynine is a highly potent painkiller. But because the liver converts mitragynine into this stronger form slowly, the overall effect on the body is blunted compared to taking a traditional opioid directly.
Pain Relief: Kratom vs. Opioid Painkillers
Kratom does produce real analgesic effects. In mouse studies using standard pain tests, 7-hydroxymitragynine was roughly five times more potent than oral mitragynine for pain relief. Some people use kratom specifically as an alternative to prescription painkillers, particularly for chronic pain conditions.
The critical difference is one of degree. Traditional opioids are full agonists that can produce profound pain relief along with profound side effects. Kratom’s partial activation of the same receptor means its pain-relieving ceiling is lower. For someone managing severe post-surgical pain, kratom would not substitute for a prescription opioid. For someone dealing with moderate chronic pain who wants to avoid prescription drugs, the partial activation is part of the appeal.
Respiratory Depression: A Major Safety Difference
The most dangerous effect of traditional opioids is respiratory depression, the slowing of breathing that causes most overdose deaths. According to the National Institute on Drug Abuse, neither kratom leaves nor mitragynine appear to cause the life-threatening breathing suppression characteristic of opioid overdoses. This is likely the single most important pharmacological distinction between kratom and drugs like heroin or fentanyl.
There is a caveat. In laboratory models, 7-hydroxymitragynine (the more potent metabolite) can cause respiratory depression that responds to naloxone, the standard opioid overdose reversal drug. But because the body converts mitragynine to this compound slowly, the buildup is generally limited enough to avoid dangerous breathing suppression under normal circumstances. Deaths associated with kratom have been reported, though in most confirmed cases the person was also using other drugs, making kratom’s specific contribution unclear.
Addiction and Withdrawal
Like opioids, kratom can produce physical dependence and withdrawal. The FDA has documented cases meeting standard criteria for substance use disorder: people using kratom longer than intended, needing increasing amounts for the same effect, experiencing cravings, and continuing use despite negative consequences in their health or personal lives.
Kratom withdrawal shares many features with opioid withdrawal. Symptoms include sweating, agitation, anxiety, vomiting, and a general flu-like feeling. Some people actually start using kratom hoping it will ease withdrawal from prescription opioids or heroin, but the Mayo Clinic notes that evidence suggests kratom can simply replace one dependency with another rather than resolving the underlying addiction. Withdrawal from traditional opioids typically lasts several days to weeks, and kratom withdrawal follows a roughly similar timeline, though individual experiences vary widely depending on dose and duration of use.
Newborns exposed to kratom during pregnancy can also experience withdrawal symptoms, including jitteriness, irritability, and muscle stiffness, a pattern similar to neonatal abstinence syndrome seen with traditional opioids.
Drug Interactions: A Unique Risk
One area where kratom may pose risks that traditional opioids don’t is in how it interacts with other medications. Mitragynine strongly inhibits several liver enzymes responsible for breaking down common drugs. It blocks more than 80% of the activity of enzymes that metabolize a wide range of medications, including many antidepressants, blood thinners, and heart drugs. If those medications aren’t broken down at their normal rate, they can build up to higher, potentially dangerous levels in your bloodstream.
This is particularly concerning because kratom is unregulated, so people often take it alongside prescription medications without realizing the interaction risk. Traditional opioids also interact with liver enzymes, but their interactions are well-documented and managed by prescribers. With kratom, no prescriber is in the loop.
Legal Status and Regulation
Unlike prescription opioids, kratom occupies a gray area in U.S. law. The FDA considers it an adulterated product: not lawfully marketed as a drug, dietary supplement, or food additive. The agency has warned consumers against using kratom, citing risks of liver toxicity, seizures, and substance use disorder. There are no FDA-approved kratom products of any kind on the U.S. market.
Kratom is not federally scheduled as a controlled substance, which means it remains available for purchase in many states. Several states and municipalities have banned it independently. This patchwork of regulation stands in sharp contrast to prescription opioids, which are tightly controlled Schedule II substances, and to illicit opioids like heroin, which are Schedule I. The lack of standardized regulation also means kratom products vary wildly in potency and purity. The FDA has flagged contamination with Salmonella bacteria and concerning levels of heavy metals in commercially sold kratom products.
Comparing Kratom to Other Substances at a Glance
- vs. prescription opioids: Same receptor target, but partial rather than full activation. Lower pain relief ceiling, lower respiratory depression risk, similar addiction potential at high and prolonged use.
- vs. coffee: Same plant family, both act as stimulants at low doses, but completely different mechanisms. Kratom engages opioid receptors; coffee blocks adenosine receptors. The comparison is mostly botanical, not pharmacological.
- vs. heroin or fentanyl: Far less potent, far less likely to cause fatal respiratory depression. Still activates opioid pathways and carries dependence risk.
- vs. over-the-counter pain relievers: Different mechanism entirely. Ibuprofen and acetaminophen do not act on opioid receptors. Kratom is closer to a weak opioid than to any OTC painkiller.
The simplest way to think about kratom is as a plant-derived partial opioid with stimulant properties at low doses. It is weaker than prescription opioids, carries a lower overdose risk, but still activates the same brain pathways that make opioids both effective and dangerous.